Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
SNDX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

24.17

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.28

EPS Last/This Y

1.5

EPS This/Next Y

1.2

Price

24.66

Target Price

39.33

Analyst Recom

1.08

Performance Q

21.86

Upside

-568.7%

Beta

0.53

Ticker: SNDX



19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09SNDX23.870.270.0511487
2026-03-10SNDX24.150.270.0911546
2026-03-11SNDX24.430.270.0711665
2026-03-12SNDX24.020.270.3511641
2026-03-13SNDX23.990.270.3511641
2026-03-17SNDX23.780.382.5517065
2026-03-18SNDX23.670.370.2016979
2026-03-19SNDX24.010.371.1216876
2026-03-20SNDX24.250.380.5516955
2026-03-23SNDX24.070.361.0415613
2026-03-24SNDX24.020.370.0215689
2026-03-25SNDX24.190.370.3415726
2026-03-26SNDX24.710.370.0415825
2026-03-27SNDX23.50.361.5816112
2026-03-30SNDX22.470.380.3416369
2026-03-31SNDX23.380.380.3416407
2026-04-01SNDX23.850.410.0316837
2026-04-02SNDX25.160.401.5216923
2026-04-06SNDX24.30.300.0315571
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09SNDX23.8845.6177.6-1.61
2026-03-10SNDX24.1645.6182.5-1.61
2026-03-11SNDX24.4144.2182.7-1.54
2026-03-12SNDX24.0044.2184.7-1.54
2026-03-13SNDX23.5344.2184.8-1.54
2026-03-17SNDX23.7844.2184.1-1.54
2026-03-18SNDX23.6644.2183.7-1.54
2026-03-19SNDX24.0144.2149.8-1.54
2026-03-20SNDX24.2344.2148.8-1.54
2026-03-23SNDX24.1044.2149.4-1.54
2026-03-24SNDX24.0244.2149.7-1.54
2026-03-25SNDX24.1944.2149.0-1.54
2026-03-26SNDX24.7044.2146.7-1.54
2026-03-27SNDX23.5144.2152.0-1.54
2026-03-30SNDX22.4844.2156.5-1.54
2026-03-31SNDX23.3739.1152.6-1.79
2026-04-01SNDX23.8539.1150.5-1.79
2026-04-02SNDX25.1539.1144.8-1.79
2026-04-06SNDX24.2939.1148.5-1.79
2026-04-07SNDX24.6639.1143.1-1.79
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09SNDX-0.86-1.1726.10
2026-03-10SNDX-0.86-1.1726.10
2026-03-11SNDX-0.86-1.1725.72
2026-03-12SNDX-0.86-1.1725.72
2026-03-13SNDX-0.86-1.1725.72
2026-03-17SNDX-0.86-1.1125.72
2026-03-18SNDX-0.86-1.1125.72
2026-03-19SNDX-0.86-1.1125.72
2026-03-20SNDX-0.86-1.1125.72
2026-03-23SNDX-0.86-1.1125.72
2026-03-24SNDX-0.86-1.1125.72
2026-03-25SNDX-0.86-1.1124.17
2026-03-26SNDX-0.86-1.1124.17
2026-03-27SNDX-0.86-1.1124.17
2026-03-30SNDX-0.86-1.1124.17
2026-03-31SNDX-0.86-1.1124.17
2026-04-01SNDX-0.86-1.1124.17
2026-04-02SNDX-0.86-1.1124.17
2026-04-06SNDX-0.86-1.1124.17
2026-04-07SNDX-0.86-1.1124.17
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-0.78

Avg. EPS Est. Current Quarter

-0.6

Avg. EPS Est. Next Quarter

-0.5

Insider Transactions

-0.86

Institutional Transactions

-1.11

Beta

0.53

Average Sales Estimate Current Quarter

73

Average Sales Estimate Next Quarter

84

Fair Value

Quality Score

34

Growth Score

39

Sentiment Score

98

Actual DrawDown %

17.4

Max Drawdown 5-Year %

-69.9

Target Price

39.33

P/E

Forward P/E

PEG

P/S

12.59

P/B

33.32

P/Free Cash Flow

EPS

-3.3

Average EPS Est. Cur. Y​

-1.79

EPS Next Y. (Est.)

-0.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-165.37

Relative Volume

0.86

Return on Equity vs Sector %

-469.1

Return on Equity vs Industry %

-452.5

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.25

EBIT Estimation

143.1
◆ SNDX Healthcare
$24.64
📉
Swing / Pullback
Buy the dip on strong trends
36 /100
WEAK
Trend
16/20
Pullback
8/25
Volume
4/15
Valuation
6/20
TP/AR
2/10
Options
0/10
RSI
58.4
Range 1M
63.9%
Sup Dist
3.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
10/25
Growth
23/30
Estimates
0/20
Inst/Vol
4/15
Options
0/10
EPS Yr
43.7%
EPS NY
64.2%
52W%
92.8%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +59.6% upside
Quality
6/30
Valuation
10/30
Growth
17/25
Stability
4/10
LT Trend
3/5
Upside
+59.6%
Quality
34
Click a card to see score breakdown Full Analysis →
Syndax Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 298
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
SNDX

Latest News

—
Caricamento notizie per SNDX…
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading